Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials. 

The breast screening provider has picked Emily Sedgwick, MD, MBA, to fill the key role and is opening new centers in Texas and Colorado.